Canaccord analyst Dewey Steadman maintained a Hold rating on Pacira Pharmaceuticals (PCRX) and raised his price target to $49 from $45. Recently reported IQVIA monthly data for August show a major acceleration of volume and revenue growth vs. a year ago as well as substantial alignment in growth trends with Symphony Health data, Steadman tells investors in a research note. Longer term, however, he remains concerned about the potential advent of competition from Heron's (HRTX) HTX-011 with what some consider to be a superior clinical data set to Exparel, and expects Pacira shares could be rangebound for the near future following strong recent performance.